Renibus Therapeutics Announces Publication of a Novel Stress Test for Assessing Antioxidant Defenses in Chronic Kidney Disease
16 juin 2020 09h00 HE
|
Rénibus Therapeutics Inc.
DALLAS, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for prevention and treatment of kidney diseases, today...
Regence and Healthmap Solutions partner to provide Kidney Health Management program to members
11 juin 2020 09h00 HE
|
Healthmap Solutions
PORTLAND, Ore., June 11, 2020 (GLOBE NEWSWIRE) -- Regence today announced a new partnership with Healthmap Solutions—a growing national Population Health Management company with a flagship Kidney...
Endonovo Therapeutics announces its collaboration with Major Universities for the Evaluation of SofPulse® for Orthopedic Surgeries
10 févr. 2020 07h30 HE
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced their SofPulse® device is being evaluated at major...
Healthmap Solutions Alerts Medicare Advantage Plans to Prepare Now for 21st Century CURES Act Implementation
29 janv. 2020 09h15 HE
|
Healthmap Solutions
TAMPA, Fla., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Healthmap Solutions, a rapidly growing national Population Health Management (PHM) company with a flagship Kidney Health Management (KHM) program, is...
Endonovo Therapeutics Provides SofPulse® To All NFL Teams
23 déc. 2019 08h30 HE
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today the delivery of SofPulse® evaluation units to all...
DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019
06 sept. 2019 09h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas Growth...
DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference
03 sept. 2019 16h15 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor...
DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
13 août 2019 16h35 HE
|
DiaMedica Therapeutics Inc.
Phase Ib study of DM199 in Chronic Kidney Disease enrollment completeEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney function (eGFR) and urine albumin (UACR) Phase II...
DiaMedica Therapeutics to Present at the 2019 Intellisight Investor Conference on August 14, 2019
12 août 2019 08h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President and CEO, will be presenting at the 2019 Intellisight Conference,...
DiaMedica Therapeutics to Report Second Quarter 2019 Financials and Provide a Business Update August 13, 2019
08 août 2019 16h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close on...